| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVITED REVIEW
Department of Medicine, Albert Einstein College of Medicine, Bronx; and The Feinstein Institute for Medical Research, Long Island Jewish Medical Center Campus, New Hyde Park, New York
The ubiquitin-proteasome system (UPS) is the major nonlysosomal pathway for intracellular protein degradation, generally requiring a covalent linkage of one or more chains of polyubiquitins to the protein intended for degradation. It has become clear that the UPS plays major roles in regulating many cellular processes, including the cell cycle, immune responses, apoptosis, cell signaling, and protein turnover under normal and pathological conditions, as well as in protein quality control by removal of damaged, oxidized, and/or misfolded proteins. This review will present an overview of the structure, biochemistry, and physiology of the UPS with emphasis on its role in the heart, if known. In addition, evidence will be presented supporting the role of certain muscle-specific ubiquitin protein ligases, key regulatory components of the UPS, in regulation of sarcomere protein turnover and cardiomyocyte size and how this might play a role in induction of the hypertrophic phenotype. Moreover, this review will present the evidence suggesting that proteasomal dysfunction may play a role in cardiac pathologies such as myocardial ischemia, congestive heart failure, and myofilament-related and idiopathic-dilated cardiomyopathies, as well as cardiomyocyte loss in the aging heart. Finally, certain pitfalls of proteasome studies will be described with the intent of providing investigators with enough information to avoid these problems. This review should provide current investigators in the field with an up-to-date analysis of the literature and at the same time provide an impetus for new investigators to enter this important and rapidly changing area of research.
heart; protein degradation
This article has been cited by other articles:
|
|
 |
|
  N. Hedhli, L. Wang, Q. Wang, E. Rashed, Y. Tian, X. Sui, K. Madura, and C. Depre Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22 Cardiovasc Res, February 1, 2008; 77(3): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Herrmann, L. O. Lerman, and A. Lerman Ubiquitin and Ubiquitin-Like Proteins in Protein Regulation Circ. Res., May 11, 2007; 100(9): 1276 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Das and V. Boggaram Proteasome dysfunction inhibits surfactant protein gene expression in lung epithelial cells: mechanism of inhibition of SP-B gene expression Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L74 - L84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang and J. Robbins Heart Failure and Protein Quality Control Circ. Res., December 8, 2006; 99(12): 1315 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Dickhout and R. C. Austin Proteasomal Regulation of Cardiac Hypertrophy: Is Demolition Necessary for Building? Circulation, October 24, 2006; 114(17): 1796 - 1798. [Full Text] [PDF]
|
|
|
|
|
|
A. V. Gomes, C. Zong, R. D. Edmondson, X. Li, E. Stefani, J. Zhang, R. C. Jones, S. Thyparambil, G.-W. Wang, X. Qiao, et al. Mapping the Murine Cardiac 26S Proteasome Complexes Circ. Res., August 18, 2006; 99(4): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
